Stratification analysis showed that MAP3K1 rs889312 AC/CC significantly reduced OS of patients with tumors smaller than or equal to 5 cm in size (HR, 3.706; 95% CI: 1.329-10.335, <i>p</i>=0.012), poorly differentiated tumors (HR, 3.002; 95% CI: 1.076-8.377, <i>p</i>=0.036) and intestinal tumors (HR, 4.780; 95% CI: 1.138-20.073, <i>p</i>=0.033).